The human immunodeficiency virus type 2 (HIV‐2) is responsible for 4.5% of AIDS cases in
Portugal. Six HIV‐2 subtypes have been described so far, subtype A being proposed as …

Human immunodeficiency virus type 1 (HIV-1) was discovered in the early 1980s when the
virus had already established a pandemic. For at least three decades the epidemic in the …

Viremia is significantly lower in HIV-2 than in HIV-1 infection, irrespective of disease stage.
Nevertheless, the comparable proviral DNA burdens observed for these two infections …

Objective To compare baseline susceptibility to protease inhibitors among HIV-1 isolates of
subtypes C, F, G and CRF02_AG, and to identify polymorphisms that determine the …

Objective: To investigate whether and how mutations at position 89 of HIV-1 protease were
associated with protease inhibitor (PI) failure, and what is the impact of the HIV-1 subtype. …

… In the Portuguese cohort, several viral failures of first-line regimens with DRV/r at 800/100
mg once daily occurred, with detection of the I50V mutation (Perpetua Gomes, personal data). …

Introduction Kidney transplant patients (KT) are at high risk for severe COVID‐19 and
presented attenuated antibody responses to vaccination when compared to immunocompetent …

Plasmacytoid dendritic cells (pDC) provide an important link between innate and acquired
immunity, mediating their action mainly through IFN-α production. pDC suppress HIV-1 …

Background Integrase strand transfer inhibitor–based regimens are recommended for first-line
therapy in human immunodeficiency virus type 2 (HIV-2). Nonetheless, dolutegravir (DTG…

Background Estimation of temporal changes in human immunodeficiency virus (HIV)
transmission patterns can help to elucidate the impact of preventive strategies and public health …